Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Evolution in Regression Patterns Following Chemoreduction for Retinoblastoma

Evolution in Regression Patterns Following Chemoreduction for Retinoblastoma CLINICAL SCIENCES Evolution in Regression Patterns Following Chemoreduction for Retinoblastoma Melis Palamar, MD; Archana Thangappan, MD; Carol L. Shields, MD Objective: To evaluate the change in regression pat- period of 56 months (median, 48 months; range, 18-145 tern following chemoreduction and tumor consolida- months), there was no change in regression patterns clas- tion therapy (thermotherapy or cryotherapy) for retino- sified as type 0, 1, or 4. However, there was evolution of blastoma. regression pattern types 2 and 3. Over time, type 2 tumor scars either remained stable (41%) or evolved to type 4 Methods: Retrospective medical record analysis was (41%), 3 (9%), or 1 (9%) scars. Type 3 tumor scars re- completed for 557 retinoblastomas (239 eyes of 157 pa- mained stable (74%) or evolved to type 1 (26%) scars. tients) that were treated with chemoreduction and showed regression to 1 of 5 patterns (type 0, no visible remnant; Conclusion: Following chemoreduction and tumor con- type 1, completely calcified remnant; type 2, completely solidation therapy, retinoblastoma regression patterns noncalcified remnant; type 3, partially calcified rem- types 2 and 3 can slowly evolve over time into a slightly nant; and type 4, atrophic chorioretinal flat scar). Evo- different appearance, even http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Evolution in Regression Patterns Following Chemoreduction for Retinoblastoma

Loading next page...
 
/lp/american-medical-association/evolution-in-regression-patterns-following-chemoreduction-for-dj34JbybTO
Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archophthalmol.2011.137
pmid
21670339
Publisher site
See Article on Publisher Site

Abstract

CLINICAL SCIENCES Evolution in Regression Patterns Following Chemoreduction for Retinoblastoma Melis Palamar, MD; Archana Thangappan, MD; Carol L. Shields, MD Objective: To evaluate the change in regression pat- period of 56 months (median, 48 months; range, 18-145 tern following chemoreduction and tumor consolida- months), there was no change in regression patterns clas- tion therapy (thermotherapy or cryotherapy) for retino- sified as type 0, 1, or 4. However, there was evolution of blastoma. regression pattern types 2 and 3. Over time, type 2 tumor scars either remained stable (41%) or evolved to type 4 Methods: Retrospective medical record analysis was (41%), 3 (9%), or 1 (9%) scars. Type 3 tumor scars re- completed for 557 retinoblastomas (239 eyes of 157 pa- mained stable (74%) or evolved to type 1 (26%) scars. tients) that were treated with chemoreduction and showed regression to 1 of 5 patterns (type 0, no visible remnant; Conclusion: Following chemoreduction and tumor con- type 1, completely calcified remnant; type 2, completely solidation therapy, retinoblastoma regression patterns noncalcified remnant; type 3, partially calcified rem- types 2 and 3 can slowly evolve over time into a slightly nant; and type 4, atrophic chorioretinal flat scar). Evo- different appearance, even

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Jun 1, 2011

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month